Increased DNA oxidative susceptibility without increased plasma LDL oxidizability in Type II diabetes: effects of alpha-tocopherol supplementation.
In vivo supplementation studies of the antioxidant alpha-tocopherol in human Type II diabetes have used surrogate, rather than direct, markers of oxidative damage/antioxidant protection and have used higher doses of alpha-tocopherol than used in coronary secondary prevention trials. We tested the hypothesis that oral alpha-tocopherol in a dosage regimen used in secondary prevention trials would reduce directly observed oxidatively induced single-strand breaks in lymphocyte DNA in Type II diabetes. We studied 40 people with Type II diabetes and 30 controls in a randomized, double-blind, placebo-controlled trial of 400 i.u. of oral alpha-tocopherol daily for 8 weeks. Lymphocyte DNA single-strand breaks and low-density lipoprotein (LDL) particle size and oxidizability were measured at baseline, after 8 weeks, and after 4 weeks washout. Polymorphisms in the gene for the antioxidant enzyme paraoxonase-1 gene (position 192) were measured. The diabetics had increased DNA oxidative susceptibility (P=0.008), without increased LDL oxidative susceptibility. There was a direct relationship between DNA oxidative susceptibility and baseline plasma alpha-tocopherol in the diabetes group alone (r=0.421, r(2)=0.177 and P=0.023), but DNA and LDL oxidative susceptibility were not influenced by alpha-tocopherol supplementation in either group in this regimen. Paraoxonase-1 gene polymorphisms did not contribute to LDL or DNA oxidative susceptibility or response to alpha-tocopherol. Increased DNA oxidative susceptibility, therefore, can occur in Type II diabetes without increased LDL oxidative susceptibility, but alpha-tocopherol supplementation in this regimen has no influence on DNA or LDL oxidative susceptibility in Type II diabetes or controls. Polymorphisms in the paraoxonase gene (position 192) are not associated with differences in oxidative susceptibility or responses to alpha-tocopherol.
Sampson
M J
MJ
Bertram Diabetes Research Unit, Department of Endocrinology and Diabetes, Norfolk and Norwich Healthcare NHS Trust, Brunswick Road, Norwich NR1 3SR, U.K. mike.sampson@norfolk-norwich.thenhs.com
Astley
S
S
Richardson
T
T
Willis
G
G
Davies
I R
IR
Hughes
D A
DA
Southon
S
S
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000378:metabolism / Q000627:therapeutic use*; D043303:Aryldialkylphosphatase; D004249:DNA Damage / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000235:genetics*; D004311:Double-Blind Method; D004950:Esterases / Q000235:genetics; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction / Q000187:drug effects; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D014810:Vitamin E / Q000097:blood / Q000627:therapeutic use*
D000975:Antioxidants; D008077:Lipoproteins, LDL; D014810:Vitamin E; D004950:Esterases; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human